WARREN, N.J., Dec. 16, 2015 (GLOBE NEWSWIRE) -- MonoSol Rx, a specialty pharmaceutical company leveraging its PharmFilm® drug delivery technology to improve patient outcomes and address unmet needs, today announced Mark Schobel, Chief Innovation and Technology Officer of MonoSol Rx, will be presenting at the 13th Annual US-Japan Symposium on Drug Delivery Systems, taking place in Lahaina, Hawaii. Mr. Schobel will give a presentation on the versatile drug delivery capabilities of MonoSol Rx’s PharmFilm® oral soluble film technology on Friday, December 18th at 4:00 PM HAST.
The US-Japan Symposium on Drug Delivery Systems is jointly sponsored by the Japanese Society of Drug Delivery Systems, Massachusetts Institute of Technology, and Kyoto University. Each year, the Symposium brings together the leading innovators from a variety of disciplines and sectors to address unmet medical needs and solutions with drug delivery technology.
Mr. Schobel will deliver a podium presentation demonstrating the capabilities of PharmFilm® as a drug delivery method for various molecules. Mark Schobel commented, “We are quite pleased to participate in this year’s US-Japan Symposium on Drug Delivery Systems. Being able to present alongside the world’s leaders in drug delivery technology is certainly an exciting opportunity for us. We are confident this symposium will further drive MonoSol Rx’s efforts to offer our patients cutting edge products in research, development, and innovation in the drug delivery space.”
MonoSol Rx currently manufactures two commercialized oral film products: Suboxone® (Buprenorphine/Naloxone) for the treatment of opioid dependence and Zuplenz® (Ondansetron) for treatment of nausea and vomiting in patients receiving chemotherapy. The Company also has expanded its clinical efforts into peptide delivery as well as additional complex molecule product candidates currently in various stages of preclinical development.
About MonoSol Rx
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® drug delivery technology to develop products that improve patient outcomes and address unmet needs. These pharmaceutical and over-the-counter products are developed independently and with partners. PharmFilm can provide a benefit to patients by improving the efficacy, safety, and convenience of currently marketed pharmaceutical products. PharmFilm enhances new pharmaceutical products with the unique, multi-faceted value proposition afforded by film delivery. MonoSol Rx's leadership in film drug delivery is supported by strong IP protection, a robust pipeline of prescription drug formulations, and two FDA-approved products — Suboxone® (buprenorphine and naloxone) sublingual film and Zuplenz® (ondansetron) oral soluble film. For press releases and other company information, visit www.monosolrx.com. More information about PharmFilm can be found at www.pharmfilm.com.
Contact: MonoSol Rx Sanford Plachter email@example.com (908) 941-1900 The Ruth Group Lee Roth (investors) firstname.lastname@example.org (646) 536-7012 Ashley Brown (media) email@example.com (646) 536-7002
Source: MonoSol Rx